1-6 of 6
Ying Yuan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Dose-Tailored Mitoxantrone Liposomes Combined with Cytarabine and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia (Non-M3) Based on Marrow Leukemic Cellularity

Li Hui, FU JIyi, Boyue Zheng, Lianjie HU, Yaqiong LI, Xin WANG, Qing HU, Li Wei, Hai Yi, Ying Yuan, Wang Huan, Yang Haiqing, Xi Yang, Hong Zheng, Yongqian Jia
Journal: Blood
Blood (2024) 144 (Supplement 1): 6068.
https://doi.org/10.1182/blood-2024-203401
Published: 2024
Journal Articles

Multiple Doses of Cnty-101, an iPSC-Derived Allogeneic CD19 Targeting CAR-NK Product, Are Safe and Result in Tumor Microenvironment Changes Associated with Response: A Case Study

Indu Ramachandran, Sarah Rothman, Mariano Clausi, Kile Mcfadden, Brenda Salantes, Gloria Jih, Thomas Brigman, Sam Kelly, Matthew S Hall, Stephanie Yee, Iphigenia Koumenis, Poulomee Das, Jordan Briggs, Tori Braun, Ying Yuan, Elizabeth Devlin, Adrienne Farid, Nikolaus S. Trede, Tamara K. Moyo, Tahir Latif, Krish Patel
Journal: Blood
Blood (2023) 142 (Supplement 1): 1654.
https://doi.org/10.1182/blood-2023-182313
Published: 2023
Journal Articles

Effectiveness and Safety of Hetrombopag-Containing Therapy in Patients with Severe Aplastic Anemia: A Multicenter Real-World Study

Hong Chang, Ling Pan, Yongqian Jia, Bing Xiang, Xiaoou Huang, Yong Guo, Meng Li, Hongyun Xing, Fang Xu, Ying Yuan, Ying Lian, Lihua Yang, Ting Niu
Journal: Blood
Blood (2023) 142 (Supplement 1): 5631.
https://doi.org/10.1182/blood-2023-185469
Published: 2023
Journal Articles

Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)

Mikkael A. Sekeres, Larisa Girshova, Vadim A Doronin, Maria Diez-Campelo, David Valcarcel, Suman Kambhampati, Nora-Athina Viniou, Dariusz Woszczyk, Raquel De Paz Arias, Argiris Symeonidis, Achilles Anagnostopoulos, Eduardo Ciliao Munhoz, Uwe Platzbecker, Valeria Santini, Robert J. Fram, Ying Yuan, Douglas V. Faller, Lionel Ades
Journal: Blood
Blood (2021) 138 (Supplement 1): 242.
https://doi.org/10.1182/blood-2021-146154
Published: 2021
Journal Articles

Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant

Meghan S. Karuturi, MD, Sally Arai, MD, Robert W. Chen, MD, Ajay K. Gopal, MD, Lei Feng, Ying Yuan, Ph.D, Scott E. Smith, MD, PhD, Stephen M. Ansell, M.D., Ph.D., Joseph D Rosenblatt, MD, Kerry J. Savage, MD MSc, Radhakrishnan Ramchandren, MD, Nancy L Bartlet, Bruce D. Cheson, MD, Andres Forero-Torres, MD, Craig H. Moskowitz, MD, Joseph M. Connors, MD, Michelle A. Fanale, MD, Sven de Vos, MD, PhD, Andreas Engert, MD, Tim Illidge, PhD, Peter Borchmann, MD, Franck Morschhauser, MD, PhD, Sandra J. Horning, M.D., Anas Younes, MD
Journal: Blood
Blood (2012) 120 (21): 3701.
https://doi.org/10.1182/blood.V120.21.3701.3701
Published: 2012
Journal Articles

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

Clinical Trials & Observations
Anas Younes, Yasuhiro Oki, Peter McLaughlin, Amanda R. Copeland, Andre Goy, Barbara Pro, Lei Feng, Ying Yuan, Hubert H. Chuang, Homer A. Macapinlac, Fredrick Hagemeister, Jorge Romaguera, Felipe Samaniego, Michelle A. Fanale, Bouthaina Shbib Dabaja, Maria A. Rodriguez, Nam Dang, Larry W. Kwak, Sattva S. Neelapu, Luis E. Fayad
Journal: Blood
Blood (2012) 119 (18): 4123–4128.
https://doi.org/10.1182/blood-2012-01-405456
Published: 2012
Includes: Supplemental data